UNVC-Due Diligence: Following the recent 19% market correction, a rigorous audit of the "FOR IMMEDIATE RELEASE" graphic posted on social media reveals critical statutory and regulatory misalignments. To protect capital, investors must look past presentation graphics and evaluate the immutable public record.
The announcement states the RELIEFTA™ patch will "transition natively into healthcare e-prescribing networks in the coming weeks" and claims it is "purpose-manufactured to bypass systemic organ toxicities." Conversely, the footnote states, "This product is not intended to diagnose, treat, cure, or prevent any disease," while asserting "strict monograph alignment."
Under 21 U.S.C. 321(g)(1)( (The Federal Food, Drug, and Cosmetic Act), any product with claims intended to affect the structure or function of the body or mitigate pain is legally classified as a drug. The disclaimer used in the footnote is a standard DSHEA (Dietary Supplement Health and Education Act) disclaimer. Under FDA regulations, if a product is a drug destined for an "e-prescribing network," it cannot legally carry a DSHEA disclaimer stating it does not treat a disease. Conversely, if it is a standard Over-the-Counter (OTC) monograph patch (like standard lidocaine), it cannot bypass organ toxicities, nor does it transition into prescription-only e-prescribing networks. The document attempts to claim the status of a prescription drug while sheltering under the disclaimer of the Dietary Supplement Health and Education Act (DSHEA) of 1994 for non-drug supplements. A product legally cannot be both.
The post claims an immediate rollout into healthcare e-prescribing networks within "the coming weeks." Under 21 C.F.R. Part 207, a National Drug Code (NDC) number is only assigned after formal electronic drug listing and registration with the FDA. If a product is operating under "strict monograph alignment" as an unapproved OTC drug, it cannot natively bypass the mandatory database onboarding gates required for clinical prescription assets. Claiming a "coming weeks" timeline without an active, verified NDC assignment is an operational impossibility.
SENDS (Self-Emulsifying Nano-Delivery System) is a generic, open-source scientific acronym used in hundreds of peer-reviewed biochemical formulations. Legally, an entity cannot own a generic scientific methodology; they can only own specific, issued utility patent claims. Without a recorded, viewable patent chain-of-title in the USPTO registry, the claim of "proprietary ownership" by 11 Three LLC remains factually unverified in the public square.
Under SEC Regulation FD (Fair Disclosure) and the SEC’s 2013 Report of Investigation (Release No. 34-69279), corporate insiders may only use social media channels to distribute material, market-moving information if investors have been explicitly notified in advance. Bypassing institutional distribution desks (like the OTC Disclosure & News Service) to post material agreements on an unannounced personal profile fails the standard for uniform public dissemination. This triggers intense regulatory scrutiny under SEC Rule 10b-5, especially because UNVC's official OTC Markets profile explicitly states:
All other means of Investor Communication: X (Twitter): N/A | Discord: N/A | LinkedIn: N/A | Facebook: N/A
Disclaimer: This post is for informational and educational purposes only and does not constitute financial, legal, or investment advice. All information is derived strictly from public records, including official USPTO databases, FDA regulations, and the issuer's public filings on OTC Markets
PL
The announcement states the RELIEFTA™ patch will "transition natively into healthcare e-prescribing networks in the coming weeks" and claims it is "purpose-manufactured to bypass systemic organ toxicities." Conversely, the footnote states, "This product is not intended to diagnose, treat, cure, or prevent any disease," while asserting "strict monograph alignment."
Under 21 U.S.C. 321(g)(1)( (The Federal Food, Drug, and Cosmetic Act), any product with claims intended to affect the structure or function of the body or mitigate pain is legally classified as a drug. The disclaimer used in the footnote is a standard DSHEA (Dietary Supplement Health and Education Act) disclaimer. Under FDA regulations, if a product is a drug destined for an "e-prescribing network," it cannot legally carry a DSHEA disclaimer stating it does not treat a disease. Conversely, if it is a standard Over-the-Counter (OTC) monograph patch (like standard lidocaine), it cannot bypass organ toxicities, nor does it transition into prescription-only e-prescribing networks. The document attempts to claim the status of a prescription drug while sheltering under the disclaimer of the Dietary Supplement Health and Education Act (DSHEA) of 1994 for non-drug supplements. A product legally cannot be both.
The post claims an immediate rollout into healthcare e-prescribing networks within "the coming weeks." Under 21 C.F.R. Part 207, a National Drug Code (NDC) number is only assigned after formal electronic drug listing and registration with the FDA. If a product is operating under "strict monograph alignment" as an unapproved OTC drug, it cannot natively bypass the mandatory database onboarding gates required for clinical prescription assets. Claiming a "coming weeks" timeline without an active, verified NDC assignment is an operational impossibility.
SENDS (Self-Emulsifying Nano-Delivery System) is a generic, open-source scientific acronym used in hundreds of peer-reviewed biochemical formulations. Legally, an entity cannot own a generic scientific methodology; they can only own specific, issued utility patent claims. Without a recorded, viewable patent chain-of-title in the USPTO registry, the claim of "proprietary ownership" by 11 Three LLC remains factually unverified in the public square.
Under SEC Regulation FD (Fair Disclosure) and the SEC’s 2013 Report of Investigation (Release No. 34-69279), corporate insiders may only use social media channels to distribute material, market-moving information if investors have been explicitly notified in advance. Bypassing institutional distribution desks (like the OTC Disclosure & News Service) to post material agreements on an unannounced personal profile fails the standard for uniform public dissemination. This triggers intense regulatory scrutiny under SEC Rule 10b-5, especially because UNVC's official OTC Markets profile explicitly states:
All other means of Investor Communication: X (Twitter): N/A | Discord: N/A | LinkedIn: N/A | Facebook: N/A
Disclaimer: This post is for informational and educational purposes only and does not constitute financial, legal, or investment advice. All information is derived strictly from public records, including official USPTO databases, FDA regulations, and the issuer's public filings on OTC Markets
PL
